MDxHealth, Inc. Enters Agreement with Celldex Therapeutics, Inc. (CLDX) for Use of MGMT Epigenetic Test in Phase III Rindopepimut Study in Brain Cancer  
12/2/2011 9:20:43 AM

IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has entered into an agreement with Celldex Therapeutics, Inc. (NASDAQ: CLDX). MDxHealth’s epigenetic MGMT test will be used during recruitment of a randomized, double-blind Phase III global clinical study of Celldex’s immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. The study has begun screening patients. Financial terms of the deal were not disclosed.